

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	12/31/1989
Sex:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	01/01/2017 12:34

Risk of Ovarian Malignancy Algorithm

ROMA, Premenopausal		4.30	Н	(Ref Interval	: <=1.14)	
ROMA, Postmenopausal		4.04	Н	(Ref Interval	: <=2.99)	
ROMA Interpretation		See Note				
-				TION: Risk of Ovarian	Malignancy	
		Algorithm The Risk of Ovarian Malignancy Algorithm (ROMA) combin results of HE4, CA125, and menopausal status into a nu score. If the patient is premenopausal, then a ROMA so less than 1.14 is consistent with a low likelihood of malignancy on surgery. If the patient is postmenopausa ROMA score of less than 2.99 is consistent with a low of finding a malignancy on surgery.				
		ROMA is intended as an aid in assessing whether a premenopausal or postmenopausal woman who presenting with an ovarian adnexal mass is at high or low likelihood of having malignancy on surgery. ROMA is indicated for women who meet the following criteria: over age 18; ovarian adnexal mass present for which surgery is planned, and who has not yet referred to an oncologist. ROMA must be interpreted in conjunction with an independent clinical and radiological assessment. ROMA is not intended as a screening or stand-alone or tumor-monitoring assay. Tumor monitoring using HE4 and/or CA125 should be ordere separately.				
		Separater	у.			
		Testing f series el	or HE4 and ectrochemil erent test	CA125 was performed us uminescent methods. An methods or kits cannot	ing Roche Cobas e alyte results obtaine	
ROMA Cancer Antigen 125		Testing f series el with diff	or HE4 and ectrochemil erent test geably.	uminescent methods. An	ing Roche Cobas e alyte results obtaine be used	
ROMA Cancer Antigen 125 ROMA Human Epididymis	Protein 4	Testing f series el with diff interchan	or HE4 and ectrochemil erent test geably. . H	uminescent methods. An methods or kits cannot	ing Roche Cobas e alyte results obtained be used : <=38)	
0 0	Protein 4	Testing f series el with diff interchan 39 U/ml 125 pmol	or HE4 and ectrochemil erent test geably. . H	uminescent methods. An methods or kits cannot (Ref Interval (Ref Interval	ing Roche Cobas e alyte results obtained be used : <=38)	
0 0	Protein 4 Accession	Testing f series el with diff interchan 39 U/ml 125 pmol	or HE4 and ectrochemil geably. . H /L	uminescent methods. An methods or kits cannot (Ref Interval (Ref Interval	ing Roche Cobas e alyte results obtained be used : <=38)	
ROMA Human Epididymis		Testing f series el with diff interchan 39 U/ml 125 pmol VERIFIED/RI	or HE4 and ectrochemil geably. . H /L PORTED DATE	uminescent methods. An methods or kits cannot (Ref Interval (Ref Interval	ing Roche Cobas e alyte results obtaine be used : <=38) : 0-140)	

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 22-060-105343 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 1 of 2 | Printed: 9/13/2022 7:25:32 AM



ROMA Interpretation	22-060-105343	3/1/2022 11:17:00 AM	3/1/2022 11:17:30 AM	3/1/2022 11:18:00 AM
ROMA Cancer Antigen 125	22-060-105343	3/1/2022 11:17:00 AM	3/1/2022 11:17:30 AM	3/1/2022 11:20:00 AM
ROMA Human Epididymis Protein 4	22-060-105343	3/1/2022 11:17:00 AM	3/1/2022 11:17:30 AM	3/1/2022 11:20:00 AM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | arupiab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 22-060-105343 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 2 | Printed: 9/13/2022 7:25:32 AM